AIM: The aim of this study is to document adverse drug reactions (ARDs) of methotrexate (MTX) in Saudi patients. METHODS: Cross sectional study of adult patients on MTX, attending rheumatology drug monitoring clinics in a university hospital, over a period of 24 weeks. Adverse drug reactions were sought by patient interview, files review and laboratory abnormalities. RESULTS: Data collected included patients' demographics, diagnoses, co-morbidities, MTX dose and duration, other medications, laboratory abnormalities and adverse reactions, their severity, preventability, and outcome. Out of a total of 593 patients screened, 186 (31.4%) using MTX were interviewed. Most of the patients were female (88.5%). Adverse drug reactions (ADRs) were detected in 61 patients (32.8%). Patients with ADRs took a mean dose of 12.9 mg (2.5-22.5 mg). Ten ADRs (16.4% of total reactions) were preventable; they ranged between severe, moderate and mild. The most common ADRs were gastrointestinal (GI) (52.5%), followed by anemia (8.2%) and chest tightness (6.6%). The duration of the reaction ranged from few hours to 4 years. CONCLUSION: In conclusion our patients with adverse reactions were younger, took less medications and had less co-morbidities. Our results were different from those published in the literature relating MTX toxicity.
AIM: The aim of this study is to document adverse drug reactions (ARDs) of methotrexate (MTX) in Saudi patients. METHODS: Cross sectional study of adult patients on MTX, attending rheumatology drug monitoring clinics in a university hospital, over a period of 24 weeks. Adverse drug reactions were sought by patient interview, files review and laboratory abnormalities. RESULTS: Data collected included patients' demographics, diagnoses, co-morbidities, MTX dose and duration, other medications, laboratory abnormalities and adverse reactions, their severity, preventability, and outcome. Out of a total of 593 patients screened, 186 (31.4%) using MTX were interviewed. Most of the patients were female (88.5%). Adverse drug reactions (ADRs) were detected in 61 patients (32.8%). Patients with ADRs took a mean dose of 12.9 mg (2.5-22.5 mg). Ten ADRs (16.4% of total reactions) were preventable; they ranged between severe, moderate and mild. The most common ADRs were gastrointestinal (GI) (52.5%), followed by anemia (8.2%) and chest tightness (6.6%). The duration of the reaction ranged from few hours to 4 years. CONCLUSION: In conclusion our patients with adverse reactions were younger, took less medications and had less co-morbidities. Our results were different from those published in the literature relating MTXtoxicity.
Entities:
Keywords:
Adverse drug reactions; Methotrexate; Saudi Arabia
Authors: Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst Journal: Arthritis Rheum Date: 2008-06-15
Authors: C H van Jaarsveld; Z N Jahangier; J W Jacobs; A A Blaauw; G A van Albada-Kuipers; E J ter Borg; H L Brus; Y Schenk; M J van Der Veen; J W Bijlsma Journal: Rheumatology (Oxford) Date: 2000-12 Impact factor: 7.580
Authors: S Major; S Badr; L Bahlawan; G Hassan; T Khogaoghlanian; R Khalil; A Melhem; R Richani; F Younes; J Yeretzian; M Khogali; R Sabra Journal: Clin Pharmacol Ther Date: 1998-10 Impact factor: 6.875
Authors: Haya Almalag; Hanan H Abouzaid; Lamya Alnaim; Jawza Albaqami; Rawan Al Shalhoub; Ibrahim Almaghlouth; Maha Dessougi; Amal Al Harthi; Mohamed Bedaiwi; Eman Alfi; Mohammed A Omair Journal: Open Access Rheumatol Date: 2020-09-07